Skip to main content
TipRanks
Go Ultimate75% OFF

10x Genomics (TXG) AI Stock Analysis

1,311 Followers
TXG

10x Genomics

(NASDAQ:TXG)

Select Model
Rating:57Neutral
Price Target:$60.00▲(4.57% Upside)
Action:reiterated
Date:11/06/26

TXG scores in the mid-range: improving fundamentals (accelerating revenue, strong gross margins, positive operating/free cash flow, and low leverage) and a constructive earnings call with raised guidance support the score. Offsetting these positives are weak price momentum (below key moving averages with negative MACD) and a valuation profile constrained by continued net losses and no dividend yield data.

Positive Factors
Revenue Growth and Gross MarginsAccelerating revenue and healthy, relatively stable gross margins indicate stronger adoption of the company’s platforms and a favorable underlying business model. If sustained, this combination can support reinvestment in product development while improving the company’s ability to convert growth into future earnings.
Negative Factors
Persistent Net LossesDespite improved revenue and cash generation, continued net losses show that the business has not yet established durable earnings profitability. This limits internal funding capacity over time and leaves results more dependent on maintaining growth and controlling expenses as the platform portfolio expands.

10x Genomics Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down revenue across different regions, revealing where 10x Genomics is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.

$0.00$50.00M$100.00M$150.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

10x Genomics' revenue growth in the Americas has been inconsistent, with a recent uptick in Q2 2025, despite a challenging funding environment. Meanwhile, APAC, particularly China, shows strong momentum with a significant year-over-year increase, bolstered by temporary purchasing activity. EMEA's revenue remains stable, but the overall landscape is pressured by declining instrument sales and academic funding challenges. The strategic acquisition of Scale Biosciences and new product launches are expected to drive future growth, though ongoing CapEx constraints and cautious customer spending pose risks.

Data provided by:The Fly

10x Genomics (TXG) vs. SPDR S&P 500 ETF (SPY)

-100%0%100%200%300%400%TXG+185.05%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$6.97B
Dividend Yield
―
Average Volume (3M)
3.36M
Price to Earnings (P/E)
-110.3
Beta (1Y)
1.66
Revenue Growth
-3.62%
EPS Growth
16.67%
Country
US
Employees
1,178
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

10x Genomics Business Overview & Revenue Model

Company Description

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated inst...

How the Company Makes Money

10x Genomics primarily makes money by selling integrated platform workflows that combine capital equipment with recurring consumables. The company’s key revenue streams are: (1) Instrument sales (capital equipment): Revenue from selling or placing in...

10x Genomics Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-1.17%|Next Earnings Date:Feb 17, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Management reported raised revenue guidance, strong consumables performance, growing Atera demand, broad customer interest, expanding AI-related opportunities, improving cash generation and progress across product and clinical initiatives. The main negatives were modest 1% total revenue growth, substantial instrument revenue declines, near-term gross margin compression from the Atera ramp, Apex-related top-line pressure and production and installation constraints.

Positive Updates

Atera Commercial Launch and Strong Customer Demand
10x Genomics began commercial shipments of Atera in September. Management said customer enthusiasm, order flow and demand momentum have continued to build, with demand not viewed as the bottleneck.

Negative Updates

Modest Overall Revenue Growth
Third-quarter revenue was $150.7 million, representing only 1% year-over-year growth.

Company Guidance

Management raised its 2026 revenue outlook to the range of $625 million to $635 million, up from $610 million to $630 million, representing 4% to 6% growth over the full year 2025 excluding nonrecurring revenue related to patent litigation settlements in both 2026 and 2025; it now expects to ship approximately 50 Atera instruments by year-end, up from the previous expectation of approximately 40, and said 50 a quarter between those constraints is about the right number going into next year. Gross margins are expected to be in the low to mid-60s for Q4, while 2027 margins will most likely come in lower than where they are because it will be an instrument heavy year and consumables will start to ramp during the course of the year; Spatial consumables in Q4 are expected to still be double digits for sure, with a full quarter of Atera consumables shipments.

10x Genomics Financial Statement Overview

Summary

Financials show an improving trajectory: TTM revenue growth accelerated to +27% with healthy ~72% gross margins, and operating/free cash flow turned solidly positive (~$100M OCF; ~$94M FCF). Balance-sheet risk appears contained with low leverage (debt-to-equity ~0.09) and a sizable equity base. The key offset is that profitability remains negative (TTM net margin about -11%) and cash-flow conversion has shown year-to-year volatility.

Income Statement

52Neutral

Balance Sheet

74Positive

Cash Flow

67Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue618.58M642.82M610.78M618.73M516.41M490.49M
Gross Profit444.65M443.88M414.48M409.31M396.02M416.40M
EBITDA44.65M3.91M-133.99M-205.11M-128.49M-24.59M
Net Income-67.08M-43.54M-182.63M-255.10M-166.00M-58.22M
Balance Sheet
Total Assets1.06B1.04B918.64M965.14M1.03B1.02B
Cash, Cash Equivalents and Short-Term Investments575.68M523.41M393.40M388.69M429.98M587.45M
Total Debt75.79M157.74M82.61M95.37M95.18M81.98M
Total Liabilities225.09M245.04M208.50M224.10M223.24M201.26M
Stockholders Equity838.04M796.33M710.13M741.04M805.74M817.57M
Cash Flow
Free Cash Flow93.77M130.12M-5.73M-64.72M-165.27M-122.65M
Operating Cash Flow99.70M136.05M6.66M-15.20M-33.61M-21.37M
Investing Cash Flow-11.35M-13.44M-32.63M133.49M-350.89M-106.73M
Financing Cash Flow5.37M6.80M10.91M13.67M15.82M35.30M

10x Genomics Technical Analysis

Technical Analysis SentimentNegative
Last Price57.38

Price Trends

50DMA73.20Negative
100DMA62.91Negative
200DMA43.32Positive

Market Momentum

MACD-4.67Positive
RSI39.96Neutral
STOCH26.10Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXG, the sentiment is Negative. The current price of 57.38 is below the 20-day moving average (MA) of 65.13, below the 50-day MA of 73.20, and above the 200-day MA of 43.32, indicating a neutral trend. The MACD of -4.67 indicates Positive momentum. The RSI at 39.96 is Neutral, neither overbought nor oversold. The STOCH value of 26.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TXG.

10x Genomics Risk Analysis

10x Genomics disclosed 10 risk factors in its most recent earnings report. 10x Genomics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price or trading volume to decline.Q3, 2026
2.We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives and corporate governance practices, including maintaining an effective system of internal controls over financial reporting.Q3, 2026
3.Risks related to our Class A common stockQ4, 2025

10x Genomics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TXG against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TECHTECH74Outperform$11.42B66.098.22%0.55%0.94%122.38%
ADPTADPT64Neutral$4.54B-62.04-37.40%―17.91%16.01%
TXGTXG57Neutral$7.55B-110.35-8.19%―-3.62%16.67%
TWSTTWST52Neutral$7.61B-53.66-23.20%―22.00%-60.49%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
MRVIMRVI48Neutral$1.87B-16.14-31.86%―10.77%46.91%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%TXGTECHTWSTADPTMRVIALMRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TXG and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TXG10X Genomics57.3839.04212.87%
TECHBio-Techne72.7011.5018.79%
TWSTTwist Bioscience111.6283.06290.83%
ADPTAdaptive Biotechnologies28.059.4450.73%
MRVIMaravai Lifesciences Holdings, Inc.7.193.4491.73%
ALMRAlamar Biosciences, Inc.28.686.6830.36%

10x Genomics Corporate Events

Executive/Board Changes

10x Genomics Appoints Two New Directors to Board

Neutral
Nov 2, 2026

On October 28, 2026, 10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors, effective immediately. Their terms were set to expire at the company’s 2028 annual meeting of stockholders, unless ended...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026